ChanaWeinstockMD

Oncology • Baltimore, MD

Clinical Instructor, Internal Medicine, University of Maryland School of Medicine

Join to view full profile

Dr. Weinstock is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Weinstock's full profile

Already have an account?

Office
22 S Greene St
Hematology Oncology, S9d10
Baltimore, MD 21201
Phone+1 410-328-7157

Fax+1 410-328-6896

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 2008 - 2011
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 2005 - 2008
Albert Einstein College of MedicineClass of 2005

Certifications & Licensure

MD State Medical License 2011 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Publications & Presentations

PubMed

FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma.
Jaleh Fallah, Brian L Heiss, Hee-Koung Joeng, Chana Weinstock, Xin Gao
Clinical Cancer Research. 2024-11-15
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.
Michael H Brave, William F Maguire, Chana Weinstock, Hui Zhang, Xin Gao
Clinical Cancer Research. 2024-11-01
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma.
Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura Fernandes
Clinical Cancer Research. 2024-08-01

Lectures

An FDA analysis of the association between adverse events and outcome in patients with urothelial cancer receiving a programmed death protein 1 or programmed death lig...
2019 ASCO Annual Meeting - 6/1/2019
Impact of antibiotic use on clinical outcomes in patients with urothelial cancer receiving a programmed death protein 1 or programmed death ligand 1 (anti-PD-1/L1) ant...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Checkpoint Inhibitors in Heavily Pretreated Bladder Ca: Long-Term DataAugust 23rd, 2019
Urothelial Carcinoma Drug Shortages: Insights From ASCO GUFebruary 6th, 2024